https://mindmedicinelaw.com/briefing/psilocybin-s-long-term-antidepressant-effects-clinical-insights-20260617-13999The Psychedelic Journalen2026-06-17T22:04:00.156832+00:00Psilocybin's Long-Term Antidepressant Effects: Clinical Insightspsilocybin, antidepressant effects, psychotherapy, depression treatment, psychedelic therapy, clinical guidelines, mental health, FDA, serotonin receptors, psychedelic researchhttps://mindmedicinelaw.com/briefing/oregon-court-case-examines-psilocybin-home-access-laws-20260616-13522The Psychedelic Journalen2026-06-17T22:04:09.198285+00:00Oregon Court Case Examines Psilocybin Home Access Lawspsilocybin, Oregon law, home access, psychedelic regulation, Measure 109, legal precedent, community practices, state policy, court case, public safetyhttps://mindmedicinelaw.com/briefing/etomidate-vs-ketamine-emergency-intubation-review-20260616-13514The Psychedelic Journalen2026-06-17T15:06:01.223798+00:00Etomidate vs Ketamine: Emergency Intubation Reviewketamine, etomidate, emergency intubation, critical care, meta-analysis, clinical trials, psychedelic research, mental health, anesthesia, public healthhttps://mindmedicinelaw.com/briefing/mescaline-s-clinical-potential-a-primer-for-clinicians-20260616-13763The Psychedelic Journalen2026-06-17T15:05:45.448097+00:00Mescaline's Clinical Potential: A Primer for Cliniciansmescaline, psychedelic therapy, clinical trials, serotonin-2A receptor, psychiatric benefits, safety profile, controlled studies, therapeutic potential, psychiatric comorbidities, psychoactive effectshttps://mindmedicinelaw.com/briefing/tiny-dose-psilocybin-pills-implications-for-clinical-trials-20260616-13840The Psychedelic Journalen2026-06-17T15:05:35.158076+00:00Tiny-Dose Psilocybin Pills: Implications for Clinical Trialspsilocybin, microdosing, clinical trials, psychedelic research, regulatory approvals, mental healthhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-sleep-in-treatment-resistant-depression-20260616-13773The Psychedelic Journalen2026-06-17T15:05:10.610664+00:00Ketamine's Impact on Sleep in Treatment-Resistant Depressionketamine, treatment-resistant depression, slow-wave activity, sleep architecture, antidepressant effects, clinical trials, neuroscience, NREM sleep, psychiatric treatment, sleep modulationhttps://mindmedicinelaw.com/briefing/psilocybin-vs-escitalopram-brain-dynamics-in-depression-20260616-13764The Psychedelic Journalen2026-06-17T15:04:57.502158+00:00Psilocybin vs. Escitalopram: Brain Dynamics in Depressionpsilocybin, escitalopram, major depressive disorder, brain dynamics, fluctuation-dissipation theorem, biomarkers, clinical trials, fMRIhttps://mindmedicinelaw.com/briefing/usc-s-first-psilocybin-study-for-mental-health-a-new-frontier-20260616-13521The Psychedelic Journalen2026-06-16T22:04:49.763999+00:00USC's First Psilocybin Study for Mental Health: A New Frontierpsilocybin, mental health, USC, clinical study, psychedelic research, therapeutic potential, serotonin receptors, policy implications, treatment paradigms, long-term effectshttps://mindmedicinelaw.com/briefing/german-biotech-licenses-ketamine-therapy-for-50m-20260616-13523The Psychedelic Journalen2026-06-16T22:04:39.588476+00:00German Biotech Licenses Ketamine Therapy for $50Mketamine therapy, prolonged-release, psychedelic market, German biotech, clinical trials, treatment efficacy, patient compliance, regulatory frameworks, psychedelic treatments, market growthhttps://mindmedicinelaw.com/briefing/australia-s-psilocybin-trial-for-concussion-symptoms-20260616-13520The Psychedelic Journalen2026-06-16T15:04:41.410895+00:00Australia's Psilocybin Trial for Concussion Symptomspsilocybin, concussion treatment, psychedelic research, Australia clinical trial, neurological conditions, psychedelic therapies, global research, regulatory implicationshttps://mindmedicinelaw.com/briefing/kmt-as-adjunct-to-cbt-for-bipolar-disorder-potential-and-challenges-20260615-13774The Psychedelic Journalen2026-06-17T22:04:34.123976+00:00KMT as Adjunct to CBT for Bipolar Disorder: Potential and Challengesketogenic metabolic therapy, cognitive behavioral therapy, bipolar disorder, mental health treatment, therapy participation, mood stability, clinical trials, psychotherapy, treatment adherencehttps://mindmedicinelaw.com/briefing/comt-gene-polymorphism-and-ocd-risk-in-bangladesh-20260615-13730The Psychedelic Journalen2026-06-17T22:04:25.662070+00:00COMT Gene Polymorphism and OCD Risk in BangladeshCOMT gene, OCD risk, Bangladesh, genetic polymorphism, Val158Met, dopamine metabolism, psychiatric disorders, case-control study, genotyping, personalized treatmenthttps://mindmedicinelaw.com/briefing/orexins-influence-epileptiform-activity-in-rat-hippocampus-20260615-13775The Psychedelic Journalen2026-06-17T22:04:17.086967+00:00Orexins Influence Epileptiform Activity in Rat Hippocampusorexins, epileptiform activity, hippocampus, orexin-A, OX1 receptor, epilepsy treatment, neuroscience, clinical trials, rat models, neuropeptideshttps://mindmedicinelaw.com/briefing/psilocybin-therapy-in-mdd-efficacy-and-research-needs-20260615-13727The Psychedelic Journalen2026-06-17T15:05:23.077541+00:00Psilocybin Therapy in MDD: Efficacy and Research Needspsilocybin therapy, major depressive disorder, systematic review, meta-analysis, clinical trials, psychedelic research, mental health treatment, evidence certainty, risk of bias, long-term efficacyhttps://mindmedicinelaw.com/briefing/exploring-societal-trauma-healing-mdma-therapy-s-role-20260615-13423The Psychedelic Journalen2026-06-16T22:05:27.893648+00:00Exploring Societal Trauma Healing: MDMA Therapy's RoleMDMA-assisted therapy, PTSD, Complex PTSD, trauma treatment, public health, regulatory challenges, community-based approaches, task-sharing models, trauma-informed carehttps://mindmedicinelaw.com/briefing/mdma-c-ptsd-navigating-societal-trauma-healing-challenges-20260615-13424The Psychedelic Journalen2026-06-16T22:05:20.075752+00:00MDMA & C-PTSD: Navigating Societal Trauma Healing ChallengesMDMA-assisted therapy, Complex PTSD, PTSD treatment, DSM classification, trauma-informed care, public health, clinical trials, insurance coverage, mental health policy, community-based interventionshttps://mindmedicinelaw.com/briefing/music-s-role-in-psychedelic-therapy-systematic-review-insights-20260615-13440The Psychedelic Journalen2026-06-16T22:05:10.802025+00:00Music's Role in Psychedelic Therapy: Systematic Review Insightspsychedelic therapy, music in therapy, psilocybin, MDMA, depressive disorders, PTSD, clinical trials, standardized protocols, therapeutic outcomes, systematic reviewhttps://mindmedicinelaw.com/briefing/dxm-s-psychedelic-potential-implications-for-research-20260615-13441The Psychedelic Journalen2026-06-16T22:05:00.364631+00:00DXM's Psychedelic Potential: Implications for Researchdextromethorphan, psychedelic research, psychiatric disorders, clinical trials, safety profile, dose-response relationship, psychoactive effects, treatment-resistant, systematic reviewhttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-mental-health-a-scoping-review-20260615-13403The Psychedelic Journalen2026-06-16T15:04:50.978424+00:00Psilocybin's Impact on Mental Health: A Scoping Reviewpsilocybin, mental health, depression, anxiety, PTSD, substance use disorders, clinical trials, equitable access, cultural adaptation, psychedelic therapyhttps://mindmedicinelaw.com/briefing/ethanol-pretrauma-worsens-ptsd-in-rats-ketamine-mitigates-20260614-13442The Psychedelic Journalen2026-06-16T15:05:48.062878+00:00Ethanol Pretrauma Worsens PTSD in Rats, Ketamine Mitigatesethanol pretrauma, PTSD in rats, intranasal ketamine, hippocampal mechanisms, alcohol and trauma, neuropeptide Y, brain-derived neurotrophic factor, hyperpolarization-activated cyclic nucleotide-gated channel, clinical trials, psychedelic researchhttps://mindmedicinelaw.com/briefing/scoping-review-on-modern-mental-health-challenges-20260613-13731The Psychedelic Journalen2026-06-17T22:04:40.547101+00:00Scoping Review on Modern Mental Health Challengesmental health challenges, integrated interventions, culturally responsive, digital mental health, climate anxiety, equity in mental healthhttps://mindmedicinelaw.com/briefing/reevaluating-head-twitch-response-in-psychedelic-research-20260613-13425The Psychedelic Journalen2026-06-16T15:05:58.735414+00:00Reevaluating Head-Twitch Response in Psychedelic Researchhead-twitch response, psychoactivity, lisuride, LSD, psychedelic research, 5HT 2A receptors, preclinical assays, behavioral effects, physiological changes, non-hallucinogenic psychedelicshttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-treating-high-risk-trd-patients-20260612-13458The Psychedelic Journalen2026-06-16T15:06:06.883586+00:00Esketamine's Role in Treating High-Risk TRD Patientsesketamine, treatment-resistant depression, suicidal ideation, intranasal administration, pharmacological strategies, mental health, NMDA receptor antagonist, psychiatric carehttps://mindmedicinelaw.com/briefing/ketamine-s-anti-suicidal-action-new-model-proposed-20260607-13511The Psychedelic Journalen2026-06-16T15:06:16.759792+00:00Ketamine's Anti-Suicidal Action: New Model Proposedketamine, anti-suicidal effects, neuroplasticity, emotional rescue, mental health treatment, clinical protocols, psychiatric interventions, therapeutic applications